bluebird bio, Inc.BLUE
NASDAQ • Healthcare
$4.97
P/E
—
PEG
—
FCF Yield
—
Rev Growth YoY
+108.4% YoY
Gross Margin
68.4%
Health Score
3/10
D/E Ratio
-11.36
Confidence
—
Business Snapshot
bluebird bio is a biotechnology company focused on developing and commercializing gene therapies for severe genetic diseases, with approved products including Zynteglo for beta-thalassemia and Skysona for cerebral adrenoleukodystrophy. The company operates in the niche, high-stakes gene therapy market, competing against other gene therapy developers and traditional treatment modalities. As a small-cap commercial-stage biotech with TTM revenue of $103.95M, it is still scaling sales while incurring significant operating losses. A defining characteristic is its dependence on reimbursement approvals and physician adoption of expensive one-time curative therapies, which creates lumpy revenue and high execution risk.
Financial Health
Gross margin improved sharply to 68.4% from 40.8% in the prior year, reflecting better product mix and manufacturing scale, but net income remains deeply negative with a TTM loss of $199.98M. Debt/equity of -11.36x indicates negative shareholders' equity, a significant balance sheet red flag, while the current ratio of 0.48x signals severe liquidity constraints...
Risk Assessment
- DEBT / LIQUIDITY — Current ratio of 0.48x indicates the company has less than half a dollar of current assets for every dollar of current liabilities, signaling near-term liquidity stress.
- FCF / CASH BURN — Free cash flow was negative $262.62M, a substantial cash burn rate relative to TTM revenue of $103.95M, requiring frequent capital raises.
- 52-WEEK POSITION — The current price of $4.97 is well below the midpoint of the 52-week range ($15.90) and near the low of $3.20, reflecting persistent weakness.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed.
- EARNINGS QUALITY — Despite beating estimates in all four recent quarters, net income was negative in each quarter, and net margin is flagged as unreliable....